BRPI0716495A2 - (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. - Google Patents

(r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.

Info

Publication number
BRPI0716495A2
BRPI0716495A2 BRPI0716495-5A2A BRPI0716495A BRPI0716495A2 BR PI0716495 A2 BRPI0716495 A2 BR PI0716495A2 BR PI0716495 A BRPI0716495 A BR PI0716495A BR PI0716495 A2 BRPI0716495 A2 BR PI0716495A2
Authority
BR
Brazil
Prior art keywords
phenoterol
pharmaceutical composition
analogue
compounds
preparation
Prior art date
Application number
BRPI0716495-5A2A
Other languages
English (en)
Inventor
Irving W Wainer
Rui Ping Xiao
Weizhong Zhu
Khalid Chakir
Farideh M Beigi
Darrell R Abernethy
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of BRPI0716495A2 publication Critical patent/BRPI0716495A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI0716495-5A2A 2006-08-10 2007-08-10 (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. BRPI0716495A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83716106P 2006-08-10 2006-08-10
US92782507P 2007-05-03 2007-05-03
PCT/US2007/075731 WO2008022038A1 (en) 2006-08-10 2007-08-10 Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure

Publications (1)

Publication Number Publication Date
BRPI0716495A2 true BRPI0716495A2 (pt) 2014-03-04

Family

ID=38917814

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716495-5A2A BRPI0716495A2 (pt) 2006-08-10 2007-08-10 (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.

Country Status (11)

Country Link
US (6) US20100168245A1 (pt)
EP (1) EP2064174B1 (pt)
JP (2) JP5302194B2 (pt)
KR (1) KR101378067B1 (pt)
CN (1) CN103739503A (pt)
AU (1) AU2007286051B2 (pt)
BR (1) BRPI0716495A2 (pt)
CA (1) CA2660707C (pt)
IL (1) IL196965A (pt)
MX (1) MX2009001534A (pt)
WO (1) WO2008022038A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022038A1 (en) * 2006-08-10 2008-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
CN101531602B (zh) * 2008-03-10 2014-08-27 北京德众万全医药科技有限公司 一种hplc法分析分离酒石酸福莫特罗中间体的方法
EP2544677A4 (en) * 2010-03-08 2013-07-10 Univ Tennessee Res Foundation BETA-ADRENERGIC RECEPTOR AGONISTS AND USES THEREOF
US9492405B2 (en) 2010-03-10 2016-11-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
KR101987841B1 (ko) 2019-03-13 2019-06-11 김도현 완구총
CN110376313B (zh) * 2019-08-20 2022-06-07 广州健康元呼吸药物工程技术有限公司 一种检测富马酸福莫特罗或其相关制剂中杂质的方法
WO2021226024A1 (en) * 2020-05-05 2021-11-11 Wainer Irving W Method for treating symptoms of viral infections
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE635889A (pt) *
AT235270B (de) 1962-08-18 1964-08-25 Chemie Linz Ag Verfahren zur Herstellung von N-substituierten Phenyläthanolaminderivaten und deren Salzen
NL300751A (pt) 1962-11-30 1900-01-01
SE354279B (pt) * 1969-06-13 1973-03-05 Draco Ab
CH564509A5 (pt) * 1969-12-12 1975-07-31 Boehringer Sohn Ingelheim
DE1962497C3 (de) * 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
DE2010883A1 (de) * 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) * 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) * 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194A (en) 1976-06-25 1978-01-10 Sekisui Jushi Kk Packing method by plastic band
ATE135721T1 (de) * 1990-07-26 1996-04-15 Monsanto Co Verfahren zur herstellung vernetzter polyamine
US6299863B1 (en) * 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US6866839B2 (en) * 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
WO1998001099A2 (en) 1996-07-05 1998-01-15 E.C. Pesterfield Assoc., Inc. Method of treating retinal ischemia and glaucoma
US6015837A (en) * 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
AU9672598A (en) 1997-09-30 1999-04-23 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) * 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
WO2000018389A2 (en) 1998-09-30 2000-04-06 The United States Of America, Represented By The Secretary, Department Of Health And Human Services USE OF A β2 ADRENERGIC RECEPTOR AGONIST IN THE TREATMENT OF CARDIOVASCULAR DISEASE
US7045658B2 (en) * 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
US20050107417A1 (en) * 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
CA2544763A1 (en) 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
JP2007530566A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用
US20080221203A1 (en) 2004-08-09 2008-09-11 University Catholique De Louvain Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease
CN101137625A (zh) * 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
WO2008022038A1 (en) * 2006-08-10 2008-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure

Also Published As

Publication number Publication date
KR20090051171A (ko) 2009-05-21
US20170081276A1 (en) 2017-03-23
AU2007286051A1 (en) 2008-02-21
US20140187645A1 (en) 2014-07-03
JP2013224316A (ja) 2013-10-31
US9522871B2 (en) 2016-12-20
WO2008022038A1 (en) 2008-02-21
IL196965A (en) 2015-10-29
JP2010500381A (ja) 2010-01-07
AU2007286051B2 (en) 2013-01-10
CN103739503A (zh) 2014-04-23
US10308591B2 (en) 2019-06-04
US20120157543A1 (en) 2012-06-21
CA2660707A1 (en) 2008-02-21
IL196965A0 (en) 2009-11-18
US20190248732A1 (en) 2019-08-15
CA2660707C (en) 2014-07-08
US20160009636A9 (en) 2016-01-14
JP5302194B2 (ja) 2013-10-02
US20180141894A1 (en) 2018-05-24
US8703826B2 (en) 2014-04-22
EP2064174A1 (en) 2009-06-03
US9908841B2 (en) 2018-03-06
EP2064174B1 (en) 2016-10-26
US10562843B2 (en) 2020-02-18
KR101378067B1 (ko) 2014-04-10
US20100168245A1 (en) 2010-07-01
MX2009001534A (es) 2009-04-08

Similar Documents

Publication Publication Date Title
BRPI0716495A2 (pt) (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0717699A2 (pt) "composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição!
BRPI0811865A2 (pt) Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
CL2007003645A1 (es) Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
IL187391A0 (en) Thiazole derivatives, their preparation and use and pharmaceutical compositions containing them
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]